References
Luckie A, Ai E. Diagnosis and management of cytomegalovirus retinitis in AIDS. Curr Opin Ophthalmol 1993; 4: 81–9
Wagstaff AJ, Bryson HM. Foscarnet: a reappraisal of its antiviral activity, pharmacokinetic properties and therapeutic use in immunocompromised patients with viral infections. Drugs 1994; 48: 199–226
Markham A, Faulds D. Ganciclovir: an update of its therapeutic use in cytomegalovirus infection. Drugs 1994; 48: 455–84
American Hospital Formulary Service Drug Information. Bethesda: American Society of Hospital Pharmacists, 1994; 404–18
1994 Physicians GenRx. New York: Data Pharmaceutica Inc., 1994; 992–6
Hirsch MS. Cytomegalovirus Infection. In Wilson JD et al. (Eds.) Harrison’s Principles of Internal Medicine. 12th ed. New York: McGraw-Hill, 1991; 692–5
Moyle G, Harman C, Mitchell S, et al. Foscarnet and ganciclovir in the treatment of CMV retinitis in AIDS patients: a randomised comparison. J Infect Dis 1992; 25: 21–7
Studies of Ocular Complications of AIDS Research Group. Mortality in patients with the acquired immune deficiency syndrome treated with either foscarnet or ganciclovir for cytomegalovirus retinitis. N Engl J Med 1992; 326: 213–20
Correspondence. N Engl J Med 1992; 326: 1701–3
Dictionnaire Vidal 1994. Paris: L’OVP-Éditions du Vidal, 1994; 589
Zidovudine still first choice in HIV treatment but early use is questioned. Drugs Ther Perspect 1993 Sep 27; 2(6): 4–7
New antiviral agents in HIV infection: didanosine and zalcitabine. Drugs Ther Perspect 1993 Feb 8; 1(2): 4–6
Oral ganciclovir for CMV retinitis. Inpharma 1994; 967: 22
Rights and permissions
About this article
Cite this article
Foscarnet or ganciclovir for CMV retinitis?. Drugs Ther. Perspect 5, 1–4 (1995). https://doi.org/10.2165/00042310-199505010-00001
Published:
Issue Date:
DOI: https://doi.org/10.2165/00042310-199505010-00001